Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(8)
•••
Post by NewToInvesting7on Feb 23, 2023 12:37pm
202 Views
Post# 35301126

Has StageZero made progress with marketing its offerings?

Has StageZero made progress with marketing its offerings?Apologies for a second post, but I wasn't aware that StageZero had actually expanded it's reach at all.  So was glad to see mention in the below articles from BlueCross Blue Shield (Rhode Island), Magellan Medical (RADMD) and ihealthcare. 

Would hope that this means increased revenues, but if the company's past performance is any indication....
 

https://www.bcbsri.com/providers/sites/providers/files/policies/2022/01/2021%20Serologic%20Genetic%20and%20Molecular%20Screening%20for%20Colorectal%20Cancer.pdf

https://www1.radmd.com/media/1013207/oncology-cancer-screening-v12023-final.pdf

https://www.ihealthcareanalyst.com/global-vitro-colorectal-cancer-testing-market/



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities